The stock of HCW Biologics Inc. (HCWB) gained in the current market after announcing its publication of a research paper in the journal Molecular Therapy. HCWB values at around $2.25, gaining more than 8% from the previously closed value. At the end of the last trading session, the stock closed at $2.07. The stock’s traded volume in the previous trading session was around 108.18K shares.
Reasons for HCWB stock gain
Today, on January 20, 2022, HCW Biologics Inc. (HCWB) announced the publication of a scientific paper by its scientific research team in the journal Molecular Therapy. The research paper aims to show that the company’s lead investigational candidate, HCW9218, can enhance the anti-tumor efficacy of chemotherapy drugs. It reduces therapy-induced senescence (TIS) to minimize the side effects.
Cellular senescence is vital in reducing a tumor, but the evidence is clear that standard cancer treatments like chemotherapy and radiation cause senescent cell accumulation in normal and tumor tissue. Senescence defends non-dividing cancer cells from chemotherapeutic drugs and radiation. It also contributes to relapse, chemoresistance, and other side effects. This publication shows that HCW9218 can significantly reduce cellular senescence caused by current chemotherapy, enhancing anti-tumor effectiveness and reducing side effects.
The FDA approved the HCW Biologics Inc. (HCWB) first-in-human Phase 1b clinical trial of HCW9218 in patients with severe pancreatic cancer in October 2021. A second investigator-initiated trial evaluating HCW9218 in patients with breast, ovarian, prostate, colorectal, and other solid tumors is also being discussed with a research facility.
The effect on the stock gain
The publication had a substantial effect on the stock of the company. The stock surged in the current market due to the positive results delivered by the company. The approval from the FDA gives it further acknowledgment due to which the stock of HCW Biologics Inc. (HCWB) was in high demand, and its stock soared.
Conclusion
HCW Biologics Inc. (HCWB) stock is gaining after its massive success in the study conducted. It is also approved by the FDA, which means it will bring a new revenue stream for the company. The company’s outlook for the future shows focusing on trials to evaluate the HCW9218 effect on patients with different cancers.
